Home > News >Latest > Sphera acquires chemical data management software company SiteHawk Sphera acquires chemical data management software company SiteHawk Sphera, the largest global provider of Integrated Risk Management software and information services with a focus on Environmental Health & Safety, Operational Risk and Product Stewardship, announces the acquisition of SiteHawk, a leading software and services provider for Safety Data Sheets (SDS) and chemical data management solutions. SiteHawk, which was founded in 1993, is based in Smyrna, Tennessee. The company’s Software as a Service products and services are designed to deliver customers a complete approach to chemical management through data, intelligence and reporting to support safety, compliance and risk management. The company’s client base includes organizations from the manufacturing, automotive, Oil & Gas and chemical manufacturing industries and more. “The acquisition of SiteHawk not only expands Sphera’s cloud-based solutions, but also extends Sphera’s Product Stewardship content, services and markets while reasserting our leadership position in the Product Stewardship space,” said Paul Marushka, Sphera’s president and CEO. “As the industry leader, we believe it is critical to continue innovating our portfolio of cloud-based and content solutions while also enhancing our world-class, on-premise products. We also want to welcome SiteHawk’s current customers and colleagues into the Sphera family.” Chemify and Prepaire Labs announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA’s Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform.Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products.Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis.We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication. With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need, said Professor Lee Cronin, Chemify's Founder and CEO.Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators. There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder, said Dr Vicent Ribas, Prepaire’s Co-Founder.About ChemputationDigital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible. Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety.About ChemifyBased in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.About Prepaire LabsPrepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE.MacDermid Enthone Industrial Solutions | January 05, 2024MacDermid Enthone Industrial Solutions, an Element Solutions Inc (ESI) company and leading surface finishing technology provider, today announced the acquisition of All-Star Chemical Company's surface finishing and cleaning chemical solutions. Going forward, All-Star's proprietary chemical solutions will be integrated into the MacDermid Enthone Industrial Solutions portfolio.We are thrilled to announce the addition of All-Star Chemical's metal finishing solutions to the MacDermid Enthone portfolio. This addition will further enhance our ongoing effort to provide industry-leading surface finishing solutions and also bring exceptional talent to our organization, said Glen Breault, Vice President, North America at MacDermid Enthone Industrial Solutions. All-Star Chemical's focus on customer service and strong partnerships within the automotive and EV sector align with our commitment to best-in-class service and industry-leading partnerships.Established in 1983, All-Star Chemical Company, a family owned and operated business, has a rich history of supplying high quality products and service to their customers. The business is headquartered in Westerville, Ohio and serves customers across the mid-western United States.Together, with the team at MacDermid Enthone, we are excited about the future, said Brian Saas, President of All-Star Chemical Co, who will be joining the MacDermid Enthone team. We are confident that this transition will provide our customers with the best avenue for growth and success.As the surface finishing industry continues to evolve, both companies are committed to securing a profitable and sustainable future for their customers and the markets they serve.About MacDermid Enthone Industrial SolutionsEstablished in 1922, MacDermid Enthone Inc., operating as MacDermid Enthone Industrial Solutions, stands as a global leader, specializing in the manufacture of chemical compounds catering to all facets of surface finishing applications. Their product portfolio includes innovative solutions designed to meet the evolving demands of the dynamic surface finishing industry and ever-changing customer requirements, with a strong focus on sustainable technologies and enhanced technical support. MacDermid Enthone Industrial Solutions operates as a business unit of Element Solutions Inc (NYSE: ESI), a diversified specialty chemicals company serving a broad spectrum of industries with innovative solutions that enhance everyday products.Arcadium Lithium plc announced the completion of the all-stock merger of equals between Allkem and Livent. The new, combined company is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. With roughly U.S. $1.9 billion of combined total revenue in 2022 and a global team of more than 2,600 employees, Arcadium Lithium is one of the largest integrated producers of lithium chemicals in the world.Paul Graves, Chief Executive Officer of Arcadium Lithium, said: As one of the leading global producers of lithium chemicals, Arcadium Lithium has the resources, scale and expertise to meet the growing needs of our rapidly changing industry. We are a leader in every major lithium extraction process – from hard rock mining to conventional pond and DLE-based brine processing – and vertically integrated, from resource to chemical manufacturing, in strategic locations around the world. This will open doors to new opportunities and strengthen our ability to deliver value to our customers, investors, employees and communities.Mr. Graves continued: It is a privilege for me to lead this great company forward with such an incredible team. This transformational merger would not have been possible without the hard work and commitment of our integration planning teams over the past months. I want to thank them and all of our employees around the world for getting us to this position. Together, we are launching an exciting new company that combines the strengths and storied legacies of two incredible organizations, both with an wavering commitment to safe, responsible and sustainable operations. We look forward to building on this strong foundation and leading our industry forward.Arcadium Lithium ordinary shares will begin trading today on the NYSE under the ticker ALTM. Arcadium Lithium also maintains a foreign exempt listing on the ASX (via the issue of CHESS Depositary Instruments (CDIs) to Allkem shareholders) and will commence trading on a normal settlement basis on the ASX under the ticker LTM at 10:00am (AEDT) on January 5, 2024. Allkem shareholders received either: (a) one Arcadium Lithium ASX listed CDI; or (b) one Arcadium Lithium NYSE listed share depending where they resided and what election (if any) they had made for each Allkem ordinary share held, except for shareholders in certain ineligible jurisdictions, who will receive cash proceeds from the sale of the Arcadium Lithium CDIs in lieu of such CDIs after closing. Livent shareholders received 2.406 Arcadium Lithium NYSE listed ordinary shares for each Livent share held.Pall Corporation, a leading provider of filtration, separation and purification solutions, introduces SepraLYTE liquid/gas coalescers, an innovative solution designed to meet the increasing demand for efficient separation of electrolyte aerosols from gas in green hydrogen production processes.Leveraging advanced separation technology, SepraLYTE coalescers excel in the separation of water or electrolyte aerosols (30% potassium hydroxide solution) from hydrogen, ensuring the purity of hydrogen produced from electrolysis processes. They are highly suitable for a wide range of separation applications where minimal pressure drop is crucial for downstream processes.Our new SepraLYTE coalescers represent Pall's commitment to serving our customers in energy transition markets. Pall continues to innovate to address new and challenging customer needs in fast growing markets like green hydrogen, said Greg Sears, Vice President and General Manager of Pall's Fluid Technologies and Asset Protection business unit.Pall's coalescers enable our customers to optimize their plant design, maximize the lifetime of their critical equipment and improve overall efficiency, reliability and output, said Sears.These coalescers feature Pall's proprietary melt blown media technology, which achieves outstanding liquid mist separation with low differential pressure. The compact design incorporates coalescer media that ensures compatibility with various chemical applications. Other key advantages of SepraLYTE liquid/gas coalescers is the ease of maintenance, compact size and waste reduction.Utilizing SepraLYTE liquid/gas coalescers, customers gain significant advantages over conventional separation products. These advantages include reliable, consistent and verifiable separation performance, high gas flow and liquid removal in a compact cartridge, which allow for smaller systems with low capital, operating, and maintenance costs.About Pall CorporationPall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of industries. Pall collaborates with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste.
#J-18808-Ljbffr
United Arab Emirates Jobs Expertini® - Ai Resume Scoring
